These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20699436)

  • 1. The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance.
    Greene LM; Nathwani SM; Bright SA; Fayne D; Croke A; Gagliardi M; McElligott AM; O'Connor L; Carr M; Keely NO; O'Boyle NM; Carroll P; Sarkadi B; Conneally E; Lloyd DG; Lawler M; Meegan MJ; Zisterer DM
    J Pharmacol Exp Ther; 2010 Nov; 335(2):302-13. PubMed ID: 20699436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel cis-restricted β-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro.
    Nathwani SM; Hughes L; Greene LM; Carr M; O'Boyle NM; McDonnell S; Meegan MJ; Zisterer DM
    Oncol Rep; 2013 Feb; 29(2):585-94. PubMed ID: 23232969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BubR1 is required for the mitotic block induced by combretastatin-A4 and a novel cis-restricted ß-lactam analogue in human cancer cells.
    Greene LM; Carr M; Keeley NO; Lawler M; Meegan MJ; Zisterer DM
    Int J Mol Med; 2011 May; 27(5):715-23. PubMed ID: 21369694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects.
    Carr M; Greene LM; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
    Eur J Med Chem; 2010 Dec; 45(12):5752-66. PubMed ID: 20933304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
    Greene LM; Kelly L; Onnis V; Campiani G; Lawler M; Williams DC; Zisterer DM
    J Pharmacol Exp Ther; 2007 Apr; 321(1):288-97. PubMed ID: 17202400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells.
    Vitale I; Antoccia A; Cenciarelli C; Crateri P; Meschini S; Arancia G; Pisano C; Tanzarella C
    Apoptosis; 2007 Jan; 12(1):155-66. PubMed ID: 17143747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combretazet-3 a novel synthetic cis-stable combretastatin A-4-azetidinone hybrid with enhanced stability and therapeutic efficacy in colon cancer.
    Greene LM; Wang S; O'Boyle NM; Bright SA; Reid JE; Kelly P; Meegan MJ; Zisterer DM
    Oncol Rep; 2013 Jun; 29(6):2451-8. PubMed ID: 23564200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells.
    Malebari AM; Greene LM; Nathwani SM; Fayne D; O'Boyle NM; Wang S; Twamley B; Zisterer DM; Meegan MJ
    Eur J Med Chem; 2017 Apr; 130():261-285. PubMed ID: 28254699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones.
    O'Boyle NM; Greene LM; Bergin O; Fichet JB; McCabe T; Lloyd DG; Zisterer DM; Meegan MJ
    Bioorg Med Chem; 2011 Apr; 19(7):2306-25. PubMed ID: 21397510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
    Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents.
    O'Boyle NM; Carr M; Greene LM; Bergin O; Nathwani SM; McCabe T; Lloyd DG; Zisterer DM; Meegan MJ
    J Med Chem; 2010 Dec; 53(24):8569-84. PubMed ID: 21080725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
    Xu D; Fang L; Zhu Q; Hu Y; He Q; Yang B
    Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-Lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells.
    Malebari AM; Fayne D; Nathwani SM; O'Connell F; Noorani S; Twamley B; O'Boyle NM; O'Sullivan J; Zisterer DM; Meegan MJ
    Eur J Med Chem; 2020 Mar; 189():112050. PubMed ID: 31954879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
    Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4,5-Diaryl-3-aminopyrazole derivatives as analogs of Combretastatin A-4: synthesis and biological evaluation.
    Liu T; Cui R; Chen J; Zhang J; He Q; Yang B; Hu Y
    Arch Pharm (Weinheim); 2011 May; 344(5):279-86. PubMed ID: 21290430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and anticancer properties of 5-arylbenzoxepins as conformationally restricted isocombretastatin A-4 analogs.
    Rasolofonjatovo E; Provot O; Hamze A; Rodrigo J; Bignon J; Wdzieczak-Bakala J; Lenoir C; Desravines D; Dubois J; Brion JD; Alami M
    Eur J Med Chem; 2013 Apr; 62():28-39. PubMed ID: 23353744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, biological evaluation and cocrystal structures with tubulin of chiral β-lactam bridged combretastatin A-4 analogues as potent antitumor agents.
    Zhou P; Liang Y; Zhang H; Jiang H; Feng K; Xu P; Wang J; Wang X; Ding K; Luo C; Liu M; Wang Y
    Eur J Med Chem; 2018 Jan; 144():817-842. PubMed ID: 29306206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, biochemical and molecular modelling studies of antiproliferative azetidinones causing microtubule disruption and mitotic catastrophe.
    O'Boyle NM; Carr M; Greene LM; Keely NO; Knox AJ; McCabe T; Lloyd DG; Zisterer DM; Meegan MJ
    Eur J Med Chem; 2011 Sep; 46(9):4595-607. PubMed ID: 21840628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSC 833 induces apoptosis in drug-sensitive human leukemia cell line and modulates resistance to paclitaxel in its multidrug-resistant variant.
    Duraj J; Takacsova X; Sedlak J; Sulikova M; Hunakova L; Bies J; Chorvath B
    Anticancer Res; 2000; 20(6B):4627-32. PubMed ID: 11205313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the multidrug resistance modulator HZ08 on the apoptosis pathway in human chronic leukaemia cell line K562/A02.
    Cen J; Zhu YL; Yang Y; Zhu JR; Fang WR; Huang WL; Li YM; Tao YF
    Arzneimittelforschung; 2011; 61(11):622-30. PubMed ID: 22232851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.